Cost of treating hepatitis C in Germany: A retrospective multicenter analysis

European Journal of Gastroenterology and Hepatology

Volumn 26, Issue 11, 2014, Pages 1278-1285

  Stahmeyer, Jona T ^a,b   Rossol, Siegbert ^a,c   Bert, Florian ^c   Antoni, Christoph ^e   Demir, Münevver ^f   Hinrichsen, Holger ^g   Hüppe, Dietrich ^h   Teuber, Gerlinde ^d   Wiebner, Bianka ^b   Wedemeyer, Heiner ^a,b   Krauth, Christian ^a,b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b GERMAN RESEARCH FOUNDATION   (Germany)

^c KRANKENHAUS NORDWEST   (Germany)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f UNIVERSITY OF COLOGNE   (Germany)

^g Practice for Gastroenterology and Hepatology   (Germany)

^h Practice for Gastroenterology   (Germany)

Author keywords

Cost of illness; Germany; Health economics; Hepatitis C; Treatment costs

Indexed keywords

PEGINTERFERON; RIBAVIRIN; ANTIVIRUS AGENT;

ADULT; AMBULATORY CARE; ARTICLE; BLOOD; COST OF ILLNESS; DECOMPENSATED LIVER CIRRHOSIS; FEMALE; GENOTYPE; GERMANY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL LEAVE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; RETROSPECTIVE STUDY; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG COST; ECONOMICS; HEALTH SERVICES RESEARCH; HEPATITIS C, CHRONIC; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA;

ADULT; ANTIVIRAL AGENTS; COST OF ILLNESS; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; FEMALE; GERMANY; HEALTH CARE COSTS; HEALTH SERVICES RESEARCH; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84927654110     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000181     Document Type: Article

References (39)

1. World Health Organization. Prevention & control of viral hepatitis infection: framework for global action. Geneva: World Health Organization; 2012.
2. Rantala M, van de Laar MJ. Surveillance and epidemiology of hepatitis B and C in Europe - a review. Euro Surveill 2008; 13:pii: 18880.
3. Cornberg M, Razavi HA, Alberti A, Bernasconi E., Buti M, Cooper C, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011; 31 (SUPPL. 2):30-60.
4. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17:107-115.
5. Poethko-Müller C, Zimmermann R, Hamouda O, Faber M, Stark K, Ross RS, Thamm M. Epidemiology of hepatitis A, B, and C among adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2013; 56:707-715.
6. Hofmann WP, Sarrazin C, Zeuzem S. Current standards in the treatment of chronic hepatitis C. Dtsch Arztebl Int 2012; 109:352-358.
7. Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 2012; 26:401-412.
8. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142:1264-1273.
9. Thein HH, Yi Q, Dore G.J., Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48:418-431.
10. Perz JF, Armstrong GL, Farrington L.A., Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45:529-538.
11. Robert Koch Institute. Situation regarding major infectious diseases in Germany - Viral Hepatitis B, C and D in 2011. Epi Bull 2012; 38:371-388.
12. Sarrazin C, Berg T, Ross R.S., Schirmacher P., Wedemeyer H, Neumann U, et al. Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection. Z Gastroenterol 2010; 48:289-351.
13. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-2416.
14. Zeuzem S, Andreone P, Pol S., Lawitz E, Diago M, Roberts S., et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364:2417-2428.
15. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski M.S., et al. SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-1206.
16. Bacon BR, Gordon SC, Lawitz E, Marcellin P., Vierling JM, Zeuzem S, et al. HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1207-1217.
17. Ghany MG, Nelson DR, Strader D.B., Thomas DL, Seeff LB. American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54:1433-1444.
18. Sarrazin C, Berg T, Cornberg M., Dollinger M, Ferenci P, Hinrichsen H., et al. Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C. Z Gastroenterol 2012; 50:57-72.
19. Gemeinsamer Bundesausschuss. Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII - Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) Telaprevir. Bundesanzeiger 2012; AT 10.05.2012; B3.
20. Gemeinsamen Bundesausschuss. Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der ArzneimittelRichtlinie (AM-RL): Anlage XII - Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach §35a des Fünften Buches Sozialgesetzbuch (SGB V) Boceprevir. Bundesanzeiger 2012; 52:1269.
21. Gordon SC, Pockros PJ, Terrault N.A., Hoop RS, Buikema A, Nerenz D, Hamzeh FM. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. Hepatology 2012; 56:1651-1660.
22. Solomon M, Bonafede M, Pan K., Wilson K, Beam C, Chakravarti P., Spiegel B. Direct medical care costs among pegylated interferon plus ribavirin-treated and untreated chronic hepatitis C patients. Dig Dis Sci 2011; 56:3024-3031.
23. Nevens F, Colle I, Michielsen P., Robaeys G, Moreno C, Caekelbergh K., et al. Resource use and cost of hepatitis C-related care. Eur J Gastroenterol Hepatol 2012; 24:1191-1198.
24. Razavi H, El Khoury AC, Elbasha E, Estes C, Pasini K., Poynard T, Kumar R. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 2013; 57:2164-2170.
25. Siebert U, Sroczynski G, Rossol S., Wasem J, Ravens-Sieberer U, Kurth BM, et al. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003; 52:425-432.
26. Siebert U, Sroczynski G. Antiviral therapy in patients with chronic hepatitis C in Germany. Clinical and economic evaluation of the initial combination therapy with interferon/peginterferon and ribavirin. Köln: DIMDI 2003; 8:1-165.
27. National Association of Statutory Health Insurance Physicians. Uniform Value Scale (EBM). Available at: http://www.kbv.de/html/ebm.php [Accessed 26 June 2013].
28. Braun S, Prenzler A, Mittendorf T., von der Schulenburg JM. Appraisal of resource use in the German health-care system from the perspective of the statutory health insurance. Gesundheitswesen 2009; 71:19-23.
29. Krauth C, Hessel F, Hansmeier T., Wasem J, Seitz R, Schweikert B. Empirical standard costs for health economic evaluation in Germany - a proposal by the working group methods in health economic evaluation. Gesundheitswesen 2005; 67:736-746.
30. Schwabe U, Paffrath D. Arzneiverordnungs-Report 2011. Berlin, Heidelberg: Springer; 2011.
31. InEK - Institute for the Hospital Remuneration System. G-DRG fee-per-case catalogue 2010. 2009.
32. National Association of Statutory Health Insurance Funds. Agreement 2010 according to § 10 Abs. 9 KHEntgG. 2009.
33. Federal Statistical Office. Statistical yearbook 2012. Berlin: Federal Statistical Office; 2012.
34. Radun D, Hamouda O. Epidemiology of hepatitis B and C in Germany. Med Welt 2004; 55:206-210.
35. Hüppe D, Zehnter E, Mauss S., Böker K, Lutz T., Racky S, et al. Epidemiology of chronic hepatitis C in Germany - an analysis of 10 326 patients in hepatitis centres and outpatient units. Z Gastroenterol 2008; 46:34-44.
36. Drummond M, Barbieri M, Cook J., Glick HA, Lis J, Malik F, et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health 2009; 12:409-418.
37. Bruno S, Crosignani A, Facciotto C., Rossi S, Roffi L, Redaelli A., et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology 2010; 51:2069-2076.
38. Cammà C, Di Bona D, Schepis F, Heathcote EJ, Zeuzem S, Pockros PJ, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004; 39: 333-342.
39. van der Meer AJ, Veldt BJ, Feld J.J., Wedemeyer H., Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308:2584-2593.